OverviewSuggest Edit

Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications. The Company's proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants as surfactant therapy has been shown to save lives in this condition. The Company believes that its proprietary technologies may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.

TypePublic
Founded1992
HQWarrington, US
Websitewindtreetx.com

Latest Updates

Employees (est.) (Apr 2019)32(+19%)
Revenue (FY, 2018)$1.8 M(+21%)
Share Price (Jan 2020)$4.3

Key People/Management at Windtree Therapeutics

Steve Simonson

Steve Simonson

Senior Vice President and Chief Development Officer
Mary B. Templeton

Mary B. Templeton

Senior Vice President, General Counsel, and Corporate Secretary
John A. Tattory

John A. Tattory

Senior Vice President and Chief Financial Officer
Kathryn A. Cole

Kathryn A. Cole

Senior Vice President, Human Resources
Craig Fraser

Craig Fraser

President and Chief Executive Officer
Show more

Windtree Therapeutics Office Locations

Windtree Therapeutics has an office in Warrington
Warrington, US (HQ)
2600 Kelly Rd #100
Show all (1)

Windtree Therapeutics Financials and Metrics

Windtree Therapeutics Revenue

Windtree Therapeutics's revenue was reported to be $1.79 m in FY, 2018
USD

Net income (Q3, 2019)

(7.1m)

EBIT (Q3, 2019)

(7.2m)

Market capitalization (8-Jan-2020)

138.4m

Closing stock price (8-Jan-2020)

4.3

Cash (30-Sept-2019)

4.4m

EV

142.7m
Windtree Therapeutics's current market capitalization is $138.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

2.8m987.0k2.0m1.5m1.8m

Cost of goods sold

517.0k2.7m929.0k

Gross profit

164.0k58.0k

Gross profit Margin, %

6%6%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

31.0k1.1m527.0k191.0k75.0k66.0k75.0k106.0k961.0k204.0k1.1m40.0k

Cost of goods sold

781.0k731.0k257.0k929.0k

Gross profit

(750.0k)362.0k270.0k(738.0k)75.0k66.0k75.0k

Gross profit Margin, %

(2419%)33%51%(386%)100%100%100%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

10.2m26.9m86.3m44.7m38.7m5.6m1.8m11.2m

Accounts Receivable

67.0k

Prepaid Expenses

442.0k719.0k777.0k821.0k362.0k512.0k422.0k507.0k

Inventories

195.0k112.0k27.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

21.5m15.4m54.8m46.0m36.1m26.4m31.3m21.2m75.9m65.6m54.9m35.6m26.1m46.3m29.4m20.3m12.4m8.0m2.5m1.8m1.9m638.0k640.0k2.1m6.1m4.4m

Accounts Receivable

41.0k22.0k

Prepaid Expenses

299.0k327.0k393.0k433.0k1.2m621.0k618.0k418.0k702.0k443.0k357.0k576.0k571.0k433.0k500.0k454.0k210.0k392.0k318.0k248.0k129.0k397.0k399.0k502.0k1.2m826.0k

Inventories

105.0k128.0k36.0k117.0k173.0k443.0k429.0k
USDY, 2019

EV/EBIT

-19.9 x

EV/CFO

-7.4 x

Financial Leverage

1.9 x
Show all financial metrics

Windtree Therapeutics Online and Social Media Presence

Embed Graph

Windtree Therapeutics News and Updates

Windtree Therapeutics Completes $26.4 Million Private Placement

WARRINGTON, Pa., Dec. 9, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that it...

Windtree Therapeutics Provides Business Update

WARRINGTON, Pa., Oct. 25, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today provided updates...

Windtree Therapeutics Announces Publication of Results of Lung Deposition Study of Aerosolized Lucinactant

WARRINGTON, Pa., Sept. 6, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the...

Windtree Therapeutics Reports First Quarter 2019 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., May 20, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Windtree Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Jan. 2, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Windtree Therapeutics, Inc. (OTC: WINT). If you...

Windtree Therapeutics to Hold Investor Call Thursday, January 3, 2019 at 8:00 a.m. EST

WARRINGTON, Pa., Jan. 2, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), will host a conference call and webcast for investors on Thursday, January 3, 2019 at 8:00 a.m. EST. This call will be the first since the Company announced the closing of an all-stock merger of a...
Show more

Windtree Therapeutics Blogs

Windtree to Host a Conference Call on December 11, 2019 to Provide Development Programs and Financial Update

Conference Call and Webcast Scheduled for Wednesday, December 11 at 8:00 a.m. EST

Windtree Announces FDA Fast Track Designation for Istaroxime

- Fast Track Designation highlights the potential for istaroxime to address unmet medical needs of patients hospitalized with acute heart failure -

Windtree Therapeutics Frequently Asked Questions

  • When was Windtree Therapeutics founded?

    Windtree Therapeutics was founded in 1992.

  • Who are Windtree Therapeutics key executives?

    Windtree Therapeutics's key executives are Steve Simonson, Mary B. Templeton and John A. Tattory.

  • How many employees does Windtree Therapeutics have?

    Windtree Therapeutics has 32 employees.

  • What is Windtree Therapeutics revenue?

    Latest Windtree Therapeutics annual revenue is $1.8 m.

  • What is Windtree Therapeutics revenue per employee?

    Latest Windtree Therapeutics revenue per employee is $55.9 k.

  • Who are Windtree Therapeutics competitors?

    Competitors of Windtree Therapeutics include Inovio Pharmaceuticals, Athersys and Reata Pharmaceuticals.

  • Where is Windtree Therapeutics headquarters?

    Windtree Therapeutics headquarters is located at 2600 Kelly Rd #100, Warrington.

  • Where are Windtree Therapeutics offices?

    Windtree Therapeutics has an office in Warrington.

  • How many offices does Windtree Therapeutics have?

    Windtree Therapeutics has 1 office.